On 5 February 2024, Glaxo Smith Kline (GSK) announced results from an interim analysis of its DREAMM-7 phase III trial. The trial compared two treatment combinations, namely:
- Blenrep® Combination: Blenrep® (belantamab mafodotin) + BorDex® (bortezomib plus dexamethasone); and
- Daratumumab combination: daratumumab + BorDex® (bortezomib plus dexamethasone)
The Blenrep® Combination showed: a) 59% further reduction in risk of disease progression or death, b) 23.2 more months of median progression-free survival, and c) 43% reduction in risk of death.